Russell Investments Group Ltd. Purchases 107,546 Shares of Edwards Lifesciences Co. (NYSE:EW)

Russell Investments Group Ltd. raised its position in Edwards Lifesciences Co. (NYSE:EW) by 27.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 500,437 shares of the medical research company’s stock after buying an additional 107,546 shares during the quarter. Russell Investments Group Ltd. owned about 0.08% of Edwards Lifesciences worth $47,076,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Castleview Partners LLC acquired a new stake in shares of Edwards Lifesciences in the 1st quarter valued at approximately $25,000. Altshuler Shaham Ltd acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $31,000. Compass Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $31,000. Jones Financial Companies Lllp acquired a new stake in shares of Edwards Lifesciences in the 1st quarter valued at approximately $33,000. Finally, Northwest Capital Management Inc acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $34,000. 79.25% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,500 shares of the company’s stock in a transaction dated Tuesday, August 29th. The shares were sold at an average price of $76.69, for a total transaction of $115,035.00. Following the sale, the vice president now directly owns 23,950 shares of the company’s stock, valued at $1,836,725.50. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,500 shares of the company’s stock in a transaction dated Tuesday, August 29th. The shares were sold at an average price of $76.69, for a total transaction of $115,035.00. Following the sale, the vice president now directly owns 23,950 shares of the company’s stock, valued at $1,836,725.50. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Michael A. Mussallem sold 29,350 shares of the company’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $75.86, for a total transaction of $2,226,491.00. Following the sale, the director now directly owns 4,486 shares in the company, valued at $340,307.96. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 179,795 shares of company stock valued at $12,724,914. 1.29% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on EW. TheStreet downgraded shares of Edwards Lifesciences from a “b-” rating to a “c+” rating in a research report on Wednesday, August 9th. Leerink Partnrs restated a “market perform” rating on shares of Edwards Lifesciences in a report on Monday, October 16th. SVB Leerink began coverage on shares of Edwards Lifesciences in a report on Monday, October 16th. They set a “market perform” rating and a $75.00 price target for the company. Citigroup lowered their price target on shares of Edwards Lifesciences from $94.00 to $85.00 and set a “buy” rating for the company in a report on Thursday, October 26th. Finally, Stifel Nicolaus lowered their price target on shares of Edwards Lifesciences from $87.00 to $70.00 and set a “hold” rating for the company in a report on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $84.29.

Edwards Lifesciences Price Performance

EW opened at $66.90 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.28 and a quick ratio of 2.45. The company has a market capitalization of $40.57 billion, a price-to-earnings ratio of 28.59, a P/E/G ratio of 3.74 and a beta of 1.02. The firm’s fifty day moving average price is $69.09 and its two-hundred day moving average price is $79.65. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $94.87.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, October 25th. The medical research company reported $0.59 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.59. The company had revenue of $1.48 billion for the quarter, compared to the consensus estimate of $1.48 billion. Edwards Lifesciences had a net margin of 24.59% and a return on equity of 24.54%. The firm’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.61 EPS. As a group, analysts anticipate that Edwards Lifesciences Co. will post 2.51 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.